289 related articles for article (PubMed ID: 21221974)
21. Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study.
Lewandowski J; Sinski M; Symonides B; Korecki J; Rogowski K; Judycki J; Sieczych A; Możeńska O; Gaciong Z
Urology; 2013 Sep; 82(3):660-5. PubMed ID: 23987161
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.
Porst H; Oelke M; Goldfischer ER; Cox D; Watts S; Dey D; Viktrup L
Urology; 2013 Sep; 82(3):667-73. PubMed ID: 23876588
[TBL] [Abstract][Full Text] [Related]
23. Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate-specific antigen in clinical routine.
Hedelin H; Johansson N; Ströberg P
Scand J Urol Nephrol; 2005; 39(2):154-9. PubMed ID: 16019770
[TBL] [Abstract][Full Text] [Related]
24. Mid term outcomes of initial 250 case experience with GreenLight 120W-HPS photoselective vaporization prostatectomy for benign prostatic hyperplasia: comparison of prostate volumes < 60 cc, 60 cc-100 cc and > 100 cc.
Hueber PA; Ben-Zvi T; Liberman D; Bhojani N; Gautam G; Deklaj T; Katz M; Zorn KC
Can J Urol; 2012 Oct; 19(5):6450-8. PubMed ID: 23040627
[TBL] [Abstract][Full Text] [Related]
25. Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial.
Carballido J; Fourcade R; Pagliarulo A; Brenes F; Boye A; Sessa A; Gilson M; Castro R
Int J Clin Pract; 2011 Sep; 65(9):989-96. PubMed ID: 21733048
[TBL] [Abstract][Full Text] [Related]
26. Diode Laser Vaporization for Benign Prostate Hyperplasia: Outcome After 126 Procedures.
Tanaka EY; Barbosa FT; Murta CB; Claro JF; Manzano JP
J Endourol; 2019 Dec; 33(12):1025-1031. PubMed ID: 31829910
[No Abstract] [Full Text] [Related]
27. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
28. Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: a large-scale Korean screening study.
Park DS; Oh JJ; Hong JY; Hong YK; Choi DK; Gong IH; Hwang JH; Kwon SW
Asian J Androl; 2013 Mar; 15(2):249-53. PubMed ID: 23353717
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia.
Mochtar CA; Kiemeney LA; van Riemsdijk MM; Barnett GS; Laguna MP; Debruyne FM; de la Rosette JJ
Eur Urol; 2003 Dec; 44(6):695-700. PubMed ID: 14644122
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of prostatic-urethral angulation on the treatment outcome of patients with symptomatic benign prostatic hyperplasia treated with tamsulosin hydrochloride.
El-Tatawy H; Gameel T; El-enen MA; Hagras A; Mousa A; El-Bahnasy AH; Raheem AA; Abu-dewan K
Arch Ital Urol Androl; 2015 Sep; 87(3):238-42. PubMed ID: 26428648
[TBL] [Abstract][Full Text] [Related]
31. Three year results of the prostatic urethral L.I.F.T. study.
Roehrborn CG; Rukstalis DB; Barkin J; Gange SN; Shore ND; Giddens JL; Bolton DM; Cowan BE; Cantwell AL; McVary KT; Te AE; Gholami SS; Moseley WG; Chin PT; Dowling WT; Freedman SJ; Incze PF; Coffield KS; Borges FD; Rashid P
Can J Urol; 2015 Jun; 22(3):7772-82. PubMed ID: 26068624
[TBL] [Abstract][Full Text] [Related]
32. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia.
Hung SF; Chung SD; Kuo HC
PLoS One; 2014; 9(1):e85588. PubMed ID: 24454896
[TBL] [Abstract][Full Text] [Related]
33. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
34. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Chung BH; Hong SJ; Cho JS; Seong DH
BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
[TBL] [Abstract][Full Text] [Related]
35. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
[TBL] [Abstract][Full Text] [Related]
36. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome.
Ozer K; Horsanali MO; Gorgel SN; Horsanali BO; Ozbek E
Urol Int; 2017; 98(4):466-471. PubMed ID: 27464069
[TBL] [Abstract][Full Text] [Related]
37. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Denmeade SR; Egerdie B; Steinhoff G; Merchant R; Abi-Habib R; Pommerville P
Eur Urol; 2011 May; 59(5):747-54. PubMed ID: 21129846
[TBL] [Abstract][Full Text] [Related]
38. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men.
Sarma AV; Burke JP; Jacobson DJ; McGree ME; St Sauver J; Girman CJ; Lieber MM; Herman W; Macoska J; Montie JE; Jacobsen SJ
Diabetes Care; 2008 Mar; 31(3):476-82. PubMed ID: 18071006
[TBL] [Abstract][Full Text] [Related]
39. Body Mass Index and Risk of Prostate Volume, International Prostate Symptom Score, Maximum Urinary Flow Rate, and Post-Void Residual in Benign Prostatic Hyperplasia Patients.
Li BH; Deng T; Huang Q; Zi H; Weng H; Zeng XT
Am J Mens Health; 2019; 13(4):1557988319870382. PubMed ID: 31426706
[TBL] [Abstract][Full Text] [Related]
40. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates.
Wang M; Guo L; Duan F; Yuan K; Zhang G; Li K; Yan J; Wang Y; Kang H
BJU Int; 2016 Jan; 117(1):155-64. PubMed ID: 25851432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
